Jubilant Pharmo (JUBLPHARMA)

FairStock Score: 53/100 — MIXED

Score breakdown: P/E: 1/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At ₹865.80, Jubilant Pharmo carries a ₹13,713 Cr market cap and trades at 39.07 times earnings and 1.93 times book. For a Graham-style bargain, the first red flag is the Graham Number of ₹489.84, leaving a margin of safety of -76.85%; DCF intrinsic value of ₹168.47 also says the market is paying far above conservative value. The P/E is rich for an ROE of 6.92% and ROCE of 9.54%, and EV/EBITDA of 105.69 suggests earnings before interest, taxes, depreciation and amortization are thin relative to enterprise value. The balance sheet is not alarming: debt/equity 0.51 and Piotroski 7/9, but Altman Z-score 2.11 is in the grey zone. Free cash flow of ₹1,584 Cr is a genuine strength and gives some support. Growth is mixed: five-year revenue CAGR of 3.89% is slow, yet recent sales growth 11.63% and profit growth 25.86% show improvement. The latest quarter had ₹2,123 Cr sales but only ₹56 Cr net profit—thin margins. Promoter holding of 47.67% is reasonable, dividend yield 0.58% is negligible. As a Buffett-style investor, I ask whether the moat justifies the price; the numbers don't show it. A high-return pharma franchise would earn more than 6.92% ROE. This looks more like a slow grower with cash flow but weak returns and a demanding valuation. I'd wait for a much lower price or clearer ROCE/ROE improvement before calling it a bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer